Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Pulmonology, University Medical Center Utrecht, The Netherlands.
Acta Oncol. 2023 Mar;62(3):237-244. doi: 10.1080/0284186X.2023.2183778. Epub 2023 Mar 16.
'Trials-within-Cohorts' (TwiCs), previously known as 'cohort multiple randomized controlled trials' is a pragmatic trial design, supporting an efficient and representative recruitment of patients for (future) trials. To our knowledge, the 'COhort for Lung cancer Outcome Reporting and trial inclusion' (COLOR) is the first TwiCs in lung cancer patients. In this study we aimed to assess the feasibility and first year results of COLOR. All patients diagnosed with lung cancer referred to the Radiotherapy department were eligible to participate in the ongoing prospective COLOR study. At inclusion, written informed consent was requested for use of patient data, participation in patient-reported outcomes (PROs), and willingness to participate in (future) trials. Feasibility was studied by assessing participation and comparing baseline PROs to EORTC reference values. First-year results of PROs at baseline and 3 months after inclusion were evaluated separately for stereotactic body radiotherapy (SBRT) and conventional radiotherapy patients. Of the 338 eligible patients between July 2020 and July 2021, 169 (50%) participated. Among these, 127 (75%) gave informed consent to PROs participation and 110 (65%) were willing to participate in (future) trials. The inclusion percentage dropped from 77% to 33% when the information procedure was switched from in-person to by phone (due to COVID-19 pandemic measures). Baseline PROs for physical and cognitive functioning were comparable in COLOR patients compared to the EORTC reference values. No significant changes in PROs were observed 3 months after inclusion, except for a slight increase in pain scores in the SBRT group ( = 97). The TwiCs-design appears feasible in lung cancer patients with fair participation rates (although negatively impacted by the COVID-19 pandemic). With a planned expansion to other centers, the COLOR-study is expected to enable multiple (randomized) evaluations of experimental interventions with important advantages for recruitment, generalizability, and long-term outcome data collection.
“队列内试验”(TwiCs),以前称为“队列多项随机对照试验”,是一种实用的试验设计,可有效地代表未来试验招募患者。据我们所知,“肺癌结局报告和试验纳入队列”(COLOR)是肺癌患者中的首个 TwiCs。在这项研究中,我们旨在评估 COLOR 的可行性和第一年的结果。所有被诊断为肺癌并转至放射治疗部门的患者均有资格参加正在进行的前瞻性 COLOR 研究。在纳入时,要求患者书面同意使用患者数据、参与患者报告的结果(PROs),并愿意参加(未来)试验。通过评估参与情况并将基线 PROs 与 EORTC 参考值进行比较来研究可行性。分别评估立体定向体部放射治疗(SBRT)和常规放射治疗患者的基线和纳入后 3 个月 PROs 的第一年结果。在 2020 年 7 月至 2021 年 7 月期间,符合条件的 338 名患者中,有 169 名(50%)参与了研究。其中,127 名(75%)同意参与 PROs 调查,110 名(65%)愿意参加(未来)试验。当信息程序从面对面改为电话(由于 COVID-19 大流行措施)时,纳入率从 77%下降到 33%。与 EORTC 参考值相比,COLOR 患者的身体和认知功能的基线 PROs 相当。纳入后 3 个月,PROs 没有明显变化,除了 SBRT 组的疼痛评分略有增加( = 97)。TwiCs 设计在肺癌患者中是可行的,参与率相当高(尽管受到 COVID-19 大流行的负面影响)。计划扩展到其他中心后,COLOR 研究预计将能够对多个(随机)实验干预进行评估,为招募、推广性和长期结果数据收集提供重要优势。